Researchers have discovered subcellular signs of young-onset Parkinson’s disease that emerge before symptoms arise. Additionally, further testing has revealed a drug that may reverse these cellular abnormalities.
The bacteria Bacillus subtilis has been found to prevent α-synuclein build up in C. elegans, offering further support to the idea that the gut microbiome can influence brain activity.
Researchers have identified that α-synuclein plays a role in DNA repair in neurons and that disruption of this function could lead to widespread death of neurons.
A peek behind the paper – Sarah Hamm-Alvarez on oligomeric α-synuclein in basal tears of Parkinson’s patients
Take a look behind the scenes of a recent paper in Biomarkers in Medicine as we ask the author about oligomeric α-synuclein in basal tears of Parkinson’s patients.
Researchers have uncovered the role of calcium and how it interacts with alpha-synuclein in the development of Parkinson’s disease.
A new study from TauRx reports success in reversing symptoms of Parkinson’s disease in mouse models treated with LTMX.
A recent study reported deposits of a protein, alpha-synuclein, in the synapses of dementia with Lewy bodies patients. The researchers believe it may be this protein that is responsible for the dementia symptoms and the progression of DLB in the brain.
Researchers have found the first evidence that autoimmunity plays a role in Parkinson’s disease, showing that T cells recognize α-synuclein peptides.
Researchers from the University of Central Florida hope to use the CRISPR Cas9 method to screen drugs for Parkinson’s disease.
The Systemic Synuclein Sampling Study (S4) is uniquely designed to identify a reproducible diagnostic and progression biomarker for Parkinson’s disease.